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Sensitivity limit of off-target cleavage assays
We used paired end sequencing to identify indels caused by genomic on-and off-target cleavage (see Supplementary Notes). Given that published studies (see the reference below) have shown that the Illumina platform has an indel rate that is several orders of magnitude lower than the ~0.1% substitution error rate, and our requirement that all called indels occur in both paired reads, the sensitivity of the high-throughput sequencing method for detecting genomic off-target cleavage in our study is limited by the amount genomic DNA (gDNA) input into the PCR amplification of each genomic target site. A 1 ng sample of human gDNA represents only ~330 unique genomes, and thus only ~330 unique copies of each genomic site are present. PCR amplification for each genomic target was performed on a total of 150 ng or 200 ng of input gDNA, which provides amplicons derived from at most 50,000 or 65,000 unique gDNA copies, respectively. Therefore, the high-throughput sequencing assay cannot detect rare genome modification events that occur at a frequency of less than approximately 1 in 50,000 (0.002%).
When comparing between two conditions, such as wt Cas9 vs. intein-Cas9, this threshold becomes approximately 10 in 50,000 (0.02%) when using the Fisher exact test and a and an anti-mouse 800CW IRDye (LI-COR) were used to visualize the gel. Lanes 1 and 2 contain purified dCas9-VP64-3×FLAG protein and lysate from untransfected HEK293 cells, respectively.
Supplementary Figure 3.
Indel frequency from high-throughput DNA sequencing of amplified genomic on-target sites ("On") and off-target sites ("Off 1-Off 4") by intein-Cas9(S219), inteinCas9(C574), and wild-type Cas9 in the presence of 4-HT. 500 ng of Cas9 expression plasmid was transfected. The higher observed efficiency of VEGF Off 1 modification than VEGF ontarget modification is consistent with a previous report. P-values are < 0.005 for the Fisher exact test (one-sided down) on all pairwise comparisons within each independent experiment of offtarget modification frequency between either intein-Cas9 variant in the presence of 4-HT versus that of wild-type Cas9 in the presence of 4-HT. P-values were adjusted for multiple comparisons using the Benjamini-Hochberg method, and are listed in Supplementary Table 5 Table 6 ) were obtained using the Fisher exact test and adjusted for multiple comparisons using the Benjamini-Hochberg Method.
Supplementary Figure 6.
Indel frequency from high-throughput DNA sequencing of amplified genomic on-target sites ("On") and off-target sites ("Off 1-Off 4") by intein-Cas9(S219), inteinCas9(C574), and wild-type Cas9 in the presence of 4-HT. Five different amounts of wild-type Cas9 expression plasmid, specified in parenthesis, were transfected. Genomic sites with low modification frequencies are enlarged in (b). P-values for comparisons between conditions (Supplementary Table 6 ) were obtained using the Fisher exact test and adjusted for multiple comparisons using the Benjamini-Hochberg Method.
Supplementary Figure 7.
DNA modification specificity of intein-Cas9(S219), inteinCas9(C574), and wild-type Cas9 in the presence of 4-HT. (a-c) On-target:off-target indel frequency ratio normalized to wild-type Cas9 (500 ng). Five different amounts of wild-type Cas9 expression plasmid, specified in parenthesis, were transfected.
Supplementary Figure 8.
Genomic EGFP disruption activity of intein-Cas9(S219) and inteinCas9(S219-G521R) in the presence of (a) β-estradiol or (b) 4-HT. Error bars reflect the standard deviation of three technical replicates. intein-Cas9(C574) vs. wt Cas9 (50 ng) EMX On < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 1 1 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 0.56 1 EMX Off 1 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 6.7 × 10 -9 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 3.7 × 10 -12 EMX Off 2 < 3.9 × 10 -16 4.3 × 10 -12 2.4 × 10 -15 1.7 × 10 -8 0.84 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 1.0 × 10 -13 7.1 × 10 -2 EMX Off 3 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 2.0 × 10 -6 1 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 7.5 × 10 -13 EMX Off 4 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 1 1 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 1.0 × 10 -11 VEGF On < 3.9 × 10 -16 < 3.9 × 10 -16 1.7 × 10 -3 1 1 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 1.9 × 10 -5 1 VEGF Off 1 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 3.8 × 10 -12 1 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 9.6 × 10 -2 VEGF Off 2 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 5.7 × 10 -2 1 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 VEGF Off 3 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 5.9 × 10 -13 1.8 × 10 -5 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 VEGF Off 4 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 1 1 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 9.9 × 10 -11 CLTA On < 3.9 × 10 -16 < 3.9 × 10 -16 1 1 1 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 1 CLTA Off 1 < 3.9 × 10 -16 < 3.9 × 10 -16 0.21 0.74 1 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 < 3.9 × 10 -16 2.0 × 10 -9
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CLTA Off 2 1.4 × 10 -4 1.6 × 10 -4 0.13 9.4 × 10 -2 0.23 4.6 × 10 -6 5.4 × 10 -6 4.8 × 10 -2 3.5 × 10 -2 0.11 
